

| -lyperca | Icemia | of M | lalign | ancy |
|----------|--------|------|--------|------|
|----------|--------|------|--------|------|

| Typoroaloonia | Tor Manghancy | | | |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
| Causes | Main mechanisms: Tumor secretion of parathyroid hormone-related protein (most common), osteolytic skeletal metastases Cancers associated with hypercalcemia: multiple myeloma (~40-50%), breast (~20%), lung (~20%), kidney, squamous cell cancers of head & neck, thyroid | | | |
| Diagnosis | Hypercalcemia is defined as a corrected calcium greater than 2.6 mmol/L | | | |
| | Corrected Ca(mmol/L) = measured Ca(mmol/L) + [0.02 x (40 - measured albumin(g/L))] | | | |
| | Severity: Mild: < 3 mmol/L Moderate: 3.0 – 3.5 mmol/L Severe: > 3.5 mmol/L | | | |
| Symptoms | Neurological: fatigue, lethargy, confusion, delirium Gastrointestinal: nausea, vomiting, constipation, abdominal pain Cardiac: bradycardia, arrhythmias Renal: polyuria, polydipsia, dehydration, impaired renal function | | | |
| Interventions | Identify and treat reversible causes | | | |
| interventions | Treat the underlying cause when possible and according to the goals of care Discontinue drugs that promote hypercalcemia (thiazide diuretics, lithium, ranitidine, vitamin A, vitamin D, calcium supplements) | | | |
| | Hydration Adequate hydration lowers serum calcium by a median of 0.25 mmol/L Mild cases: initiate oral hydration of at least 6-8 glasses of water/day Moderate-severe cases: initiate NS 100-120mL/hr IV or by hypodermoclysis | | | |
| | Pharmacological IV Bisphosphonates (eg. pamidronate, zoledronic acid) Give if corrected Ca ≥ 3 or symptomatic and in line with goals of care Long onset of action (~48 hrs) and long duration of action (3-6 weeks) Don't give until fully rehydrated with adequate urine output Contraindicated if creatinine >400 μmol/L or creatinine clearance <10 mL/min IV Calcitonin Quick onset of action (~4 hrs) but becomes ineffective after 48 hours Useful when rapid lowering of calcium is required Needs to be given in combination with a bisphosphonate *For dosing information refer to Northern Health Palliative Care Program Symptom Guidelines 4th ed. | | | |

Northern Health Palliative Care Program Symptom Guidelines 4th Edition (2019) UpToDate: Treatment of Hypercalcemia

